会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Methods for diagnosing benign prostatic diseases
    • 诊断良性前列腺疾病的方法
    • US6100049A
    • 2000-08-08
    • US257407
    • 1999-02-25
    • Albert A. LudererGrant D. CarlsonRobert P. ThielThomas F. SorianoWilliam J. Kramp
    • Albert A. LudererGrant D. CarlsonRobert P. ThielThomas F. SorianoWilliam J. Kramp
    • G01N33/573G01N33/574G01N33/68
    • G01N33/68G01N33/57434
    • The present invention relates to novel methods for diagnosing benign prostatic diseases (BPD), such as benign prostatic hyperplasia, prostatitis, or glandular atrophy, in a male human patient without requiring a biopsy. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between about 2.5 ng/ml and 10.0 ng/ml, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA to total PSA is calculated. If this proportion is equal to or greater than about 25%, then the patient is diagnosed as having BPD. Optionally, if the patient has a total PSA level of between 10.1 ng/ml and 20.0 ng/ml, then the free PSA level in the blood or serum of the patient can also be measured. The proportion of free PSA to total PSA is calculated. If this proportion is equal to or greater than about 25%, then the patient is diagnosed as having BPD.
    • 本发明涉及在男性人类患者中诊断良性前列腺疾病(BPD),例如良性前列腺增生,前列腺炎或腺体萎缩的新方法,而不需要活组织检查。 测量患者血液或血清中的总前列腺特异性抗原(PSA)水平。 如果患者的总PSA水平在约2.5ng / ml至10.0ng / ml之间,则测量患者的血液或血清中的游离PSA水平。 计算游离PSA与总PSA的比例。 如果该比例等于或大于25%,那么患者被诊断为具有BPD。 任选地,如果患者的总PSA水平在10.1ng / ml和20.0ng / ml之间,则也可以测量患者的血液或血清中的游离PSA水平。 计算游离PSA与总PSA的比例。 如果该比例等于或大于25%,那么患者被诊断为具有BPD。